文献速递介入腹部CTMR

深度学习模型预测中期肝癌TACE生存预后

Development and validation of a deep learning model for survival prognosis of transcatheter arterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma.
PubMed 文献 · Eur J Radiol · 2022-09-19

本研究基于EfficientNetV2构建深度学习模型,用于评估初治中期肝细胞癌患者TACE治疗的进展时间(TTP)和总生存期(OS)。使用一个中心414例患者训练和验证TTP模型,另一个中心129例患者作为测试集同时评估TTP和OS。模型评分≤0.5的患者TTP和OS均显著优于高分者,且性能优于影像组学和临床模型。

要点

  • 模型评分≤0.5提示TACE后TTP和OS获益更佳。
  • 深度学习模型预测性能优于影像组学和临床模型。
  • 可用于辅助临床决策TACE治疗选择。
英文原文(摘要)· 点击展开

PURPOSE: We aimed to develop a deep learning-based approach to evaluate both time-to-progression (TTP) and overall survival (OS) prognosis of transcatheter arterial chemoembolization (TACE) in treatment-naïve patients with intermediate-stage hepatocellular carcinoma (HCC) and compare the approach's performance with those of radiomics and clinical models.

METHODS: EfficientNetV2 was used to build a prognosis model for treatment-naïve patients with HCC. Data of 414 intermediate-stage HCC patients from one participant center were collected to construct the training and validation datasets (70%:30%) for TTP prognosis, while data of 129 intermediate-stage HCC patients from another participant center were collected as the test dataset for both TTP and OS prognosis. Three radiomics and three clinical models were then constructed for comparison.

RESULTS: Patients with EfficientNetV2-based model score ≤ 0.5 had better TTP than those with higher scores (hazard ratio [HR]: 0.32, 95%CI: 0.22-0.46, P < 0.0001; HR: 0.28, 95%CI: 0.20-0.41, P < 0.0001; and HR: 0.55, 95%CI: 0.36-0.88, P = 0.005 in the training, validation, and test datasets, respectively). Patients with model score ≤ 0.5 had better OS (38.8 months vs 20.9 months, HR: 0.58, 95%CI: 0.37-0.90, P = 0.008). Compared with the radiomics (intra-tumoral and peri-tumoral) and three clinical models, the EfficientNetV2-based model showed better survival prognosis for TACE (P < 0.05) in the test dataset.

CONCLUSIONS: The EfficientNetV2-based model enables assessment of both TTP and OS prognosis of TACE in treatment-naïve, intermediate-stage HCC. Patients with lower scores will benefit from TACE. The model can potentially be used by clinicians to improve decision making regarding TACE treatment choices.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Wang, Liu, Xu, et al. Development and validation of a deep learning model for survival prognosis of transcatheter arterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma. Eur J Radiol. 2022. PMID: 36152524. doi:10.1016/j.ejrad.2022.110527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。